Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00981
|
|||||
| Drug Name |
Eletriptan
|
|||||
| Synonyms |
(R)-3-[(1-Methyl-2-pyrrolidinyl)methyl]-5-[2-(phenylsulfonyl)ethyl]-1H-Indole; (R)-5-[2-(Benzenesulfonyl)ethyl]-3-[(N-methylpyrrolidin-2-yl)methyl]-1H-indole; 3-(((R)-1-Methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)indole; 3-{[(2R)-1-methylpyrrolidin-2-yl]methyl}-5-[2-(phenylsulfonyl)ethyl]-1H-indole; 5-[2-(benzenesulfonyl)ethyl]-3-[[(2R)-1-methylpyrrolidin-2-yl]methyl]-1H-indole; Eletriptan (INN); Eletriptan [INN:BAN]; Eletriptanum; Relpax; Relpax (TN); UK 116044; UK-116044; UK-116044-04; UK116044
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Migraine Headaches [ICD11: 8A80] | Approved | [1] | |||
| Therapeutic Class |
Antimigraine Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C22H26N2O2S
|
|||||
| Canonical SMILES |
CN1CCCC1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4
|
|||||
| InChI |
InChI=1S/C22H26N2O2S/c1-24-12-5-6-19(24)15-18-16-23-22-10-9-17(14-21(18)22)11-13-27(25,26)20-7-3-2-4-8-20/h2-4,7-10,14,16,19,23H,5-6,11-13,15H2,1H3/t19-/m1/s1
|
|||||
| InChIKey |
PWVXXGRKLHYWKM-LJQANCHMSA-N
|
|||||
| CAS Number |
CAS 143322-58-1
|
|||||
| Pharmaceutical Properties | Molecular Weight | 382.5 | Topological Polar Surface Area | 61.6 | ||
| Heavy Atom Count | 27 | Rotatable Bond Count | 6 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 3 | |||
| XLogP |
4.1
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
ChEBI:50922
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Eletriptan was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.